Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of TUB-040, in Combination With Standard Ovarian Cancer Drugs in Patients With High-grade Epithelial Serous or Endometrioid Epithelial Ovarian Cancer OC)

NCT07736937 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT07736937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07736937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of TUB-040, in Combination With Standard Ovarian Cancer Drugs in Patients With High-grade Epithelial Serous or Endometrioid Epithelial Ovarian Cancer OC)
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 30, 2026
Completion date
April 30, 2028
Enrollment
72 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer